Target concentration intervention: Beyond Y2K

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 9-13

  Holford, Nicholas H G ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Target concentration intervention; Therapeutic drug monitoring

Indexed keywords

ARTICLE; DRUG MONITORING; DRUG TARGETING; MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 0032986608     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00971.x     Document Type: Article

References (23)

1. 1 Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol 1998; 46: 93-94.
2. 2 Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 1998; 46: 95-99.
3. 3 Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. Br J Clin Pharmacol 1998; 46: 185-193.
4. 4 Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 1998; 46: 307-319.
5. 5 Holford NHG, Tett S. Therapeutic Drug Monitoring. The strategy of target concentration intervention. In Avery's Drug Treatment, 4th edn. ed Speight T, Holford NHG. Adis Intl, Auckland, 1997: pp. 225-259.
6. 6 Sheiner LB, Tozer TN. Clinical pharmacokinetics: The use of plasma concentrations of drugs. In Clinical Pharmacology: Basic Principles of Therapeutics Eds Melmon KL, Morelli HF. Macmillan, New York, 1978: pp. 71-109.
7. 7 Holford NHG. The clearance and volume method of dose prediction. In Avery's Drug Treatment, 4th edn. ed Speight T, Holford NHG. Adis Intl, Auckland, 1997: pp. 1791-1798.
8. 8 Holford NHG. Population models for Alzheimer's and Parkinson's disease. In The Population Approach: Measuring and Managing Variability in Response Concentration and Dose, eds. Aarons L, Balant LP, et al. European Commission, Brussels. 1997.
9. 9 Holford NHG, Black P, Briant R, Couch R, Kennedy J. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial. Clin Pharmacokin 1993; 25: 495-505.
10. 10 Holford NHG, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak How following acute airways obstruction. Population analysis of a randomised concentration controlled trial. Clin Pharmacokin 1993; 25: 506-515.
11. 11 Holford NHG, Sheiner LB. Understanding the Dose Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models. Clin Pharmacokin 1981; 6: 429-453.
12. 12 Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46: 321-333.
13. 13 Beal S, Sheiner LB. NONMEM, Version V. 1998.
14. 14 Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998; 9: 1463-1468.
15. 15 Karlsson MO, Sheiner LB. The importance of modelling inter-occasion variability in population pharmacokinetic analyses. J Pharmacokin Biopharm 1993; 21: 735-750.
16. 16 Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clin Pharmacokin 1985; 10: 1-37.
17. 17 Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. Clin Pharmacokin 1998; 34: 57-77.
18. 18 Morris RG. Target concentration strategy for cyclosporin monitoring. Clin Pharmacokin 1997; 32: 175-179.
19. 19 Johnston A, Holt DW. Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol 1999; 47: 339-350.
20. 20 Begg EJ, Barclay ML, Kirkpatrick CJM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999; 47: 23-30.
21. 21 Sanathanan LP, Peck CC. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control Clin Trials 1901; 12: 780-794.
22. 22 Endrenyi L, Zha J. Comparative efficiencies of randomized concentration-and dose controlled clinical trials. Clin Pharmacol Ther 1994; 56: 331-338.
23. 23 Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505.